Cell – ECM interactions play distinct and essential roles at multiple stages during

the development of the aortic arch arteries

Michael Warkala[1,2, §], Dongying Chen[3, §, ¥], Ali Jubran[3, †], AnnJosette Ramirez[1,4, †],

Michael Schonning[1,4], Xia Wang[†], Huaning Zhao[4], and Sophie Astrof[1, 2, 4, *].

1. Department of Cell Biology and Molecular Medicine, New Jersey Medical School,

Rutgers Biomedical and Health Sciences, Newark, NJ, USA

2. Multidisciplinary Ph.D. Program in Biomedical Sciences: Molecular Biology, Genetics,

and Cancer Track, New Jersey Medical School, Rutgers Biomedical and Health

Sciences, Newark, NJ, USA

3. Graduate Program in Cell & Developmental Biology, Thomas Jefferson University,

Philadelphia, PA, USA

4. Multidisciplinary Ph.D. Program in Biomedical Sciences: Cell Biology, Neuroscience

and Physiology Track, New Jersey Medical School, Rutgers Biomedical and Health

Sciences, Newark, NJ, USA

¥ Current address: Yale Cardiovascular Research Center, Department of Internal

Medicine, Yale University School of Medicine, New Haven, CT 06511, USA.

‡ Current address: Department of Anatomy, Histology & Developmental Biology, School

of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen,

China

§ These individuals contributed equally to the manuscript as co-first authors

† These individuals contributed equally to the manuscript as co-second authors

Short title: Integrin $\alpha5\beta1$ and Fn1 in arch artery formation

* Corresponding author: Sophie Astrof,

sophie.astrof@rutgers.edu

185 South Orange Ave,

Medical Sciences Building, Room I-518,

Newark, NJ, 01703

Total word count: 7746

Subject Codes: Animal Models of Human Disease; Mechanisms; Vascular Biology;

Rationale: Defects in the morphogenesis of the 4th pharyngeal arch arteries (PAAs) give rise to lethal birth defects. Understanding genes and mechanisms regulating PAA formation will provide important insights into the etiology and treatments for congenital heart disease.

Objective: Cell-ECM interactions play essential roles in the morphogenesis of PAAs and their derivatives, the aortic arch artery (AAA) and its major branches; however, their specific functions are not well-understood. Previously, we demonstrated that integrin $\alpha5\beta1$ and fibronectin (Fn1) expressed in the *Isl1* lineages regulate PAA formation. The objective of these studies was to investigate cellular mechanisms by which integrin $\alpha5\beta1$ and Fn1 regulate AAA morphogenesis.

Methods and Results: Using temporal lineage tracing, whole-mount confocal imaging, and quantitative analysis of the second heart field (SHF) and endothelial cell (EC) dynamics, we show that the majority of PAA EC progenitors arise by E7.5 in the SHF and populate pharyngeal arch mesenchyme between E7.5 and E9.5. Consequently, SHF-derived ECs in the pharyngeal arches become organized into a uniform plexus of small blood vessels, which becomes remodeled into the PAAs between 31 – 35 somites. The remodeling of the vascular plexus is orchestrated by signals dependent on pharyngeal ECM microenvironment and extrinsic to the endothelium. Conditional ablation of integrin $\alpha5\beta1$ or Fn1 in the Isl1 lineages showed that signaling by the ECM regulates AAA morphogenesis at multiple steps: 1) the recruitment of the SHF-derived ECs into the pharyngeal arches, 2) the remodeling of the uniform EC plexus in the 4th arches into the PAAs; and 3) differentiation of neural crest-derived cells abutting the PAA endothelium into vascular smooth muscle cells.

Conclusions: PAA formation is a multi-step process entailing dynamic contribution of

SHF-derived ECs to pharyngeal arches, the remodeling of endothelial plexus into the

PAAs, and the remodeling of the PAAs into the AAA and its major branches. Cell-ECM

interactions regulated by integrin $\alpha5\beta1$ and Fn1 play essential roles at each of these

developmental stages.

Key Words: integrin $\alpha5\beta1$, fibronectin, second heart field, endothelial progenitor cells,

pharyngeal arch arteries, aortic arch arteries

Nonstandard Abbreviations and Acronyms in the Alphabetical Order: AAA – aortic

arch artery; CHD – congenital heart disease; ECs – endothelial cells; Fn1 – fibronectin;

IAA-B – interrupted aortic arch type B; Itga5 – integrin $\alpha5$; PAA – pharyngeal arch

arteries; RERSA – retro-esophageal right subclavian artery; SHF – second heart field;

VEGFR2 – vascular endothelial growth factor receptor 2

Introduction

Aortic arch artery (AAA) and its major branches comprise an asymmetrical vascular tree that routes oxygenated blood from the heart into the systemic circulation [1]. Defects in the development of the AAA cause devastating forms of congenital heart disease (CHD) due to interruption(s) in the aortic arch, of which interrupted aortic arch type B (I-AAB) is more prevalent [2, 3]. Non-lethal defects in aortic arch morphogenesis such as vascular rings can impact the quality of life by causing constriction of the trachea and esophagus, and resulting in difficulties with eating, breathing, and also in dizziness, vertigo, or tinnitus [4].

The AAA and its major branches develop from the remodeling of three bilaterally symmetrical pairs of pharyngeal arch arteries (PAA), numbered 3, 4, and 6 [5]. It is important to note that phenotypically identical AAA defects arise due to either defects in PAA formation or defects in the remodeling of initially well-formed, symmetrical PAAs into asymmetric AAAs [6]. PAAs arise by vasculogenesis from endothelial precursors originating in the lateral plate mesoderm, also known as the second heart field (SHF) [7-13]. Experiments in zebrafish and mice have demonstrated that PAA formation is a multi-stage process that entails endothelial specification in the SHF, migration of SHF-derived endothelial progenitors into the pharyngeal region, differentiation into ECs, and the assembly of SHF-derived ECs into a plexus of small blood vessels [9, 13-16]. Thereafter, the pharyngeal endothelial plexus becomes connected with the ventral and dorsal aortae. The endothelium of the ventral aortae also forms by vasculogenesis from SHF-derived progenitors and is contiguous with the cardiac outflow tract and the PAAs [9, 11]. Following pharyngeal arch segmentation, the plexus endothelium within each arch is

rearranged into the PAAs [9]. The 3rd PAA is evident by E9.5, before the 4th and 6th PAAs

are formed. By the evening of E10.5, all three symmetrical pairs of PAAs are formed.

Defects in the formation of the left 4th PAA lead to I-AAB, which is lethal unless

corrected by surgery soon after birth [2]. Following PAA formation, neural crest-derived

cells closest to the PAA endothelium differentiate into vascular smooth muscle cells

(VSMCs), surrounding the PAA endothelium with a VSMC coat by E12.5 [17-21]. While not

essential for PAA formation, the differentiation of neural crest (NC)-derived cells into

VSMCs is essential for the stability of the PAAs, and for their eventual remodeling into

the asymmetrical AAA and its branches; Defects in NC differentiation in the 4th

pharyngeal arch lead to arch artery regression, and IAA-B [19, 20, 22]. In summary, I-AAB

results either due to defects in the formation of the left 4th PAA or due to its regression.

Morphogenesis of distinct organs and structures proceeds within niches

comprised of distinct complements of extracellular matrix (ECM) proteins, and

alterations in ECM microenvironment can severely affect embryogenesis [23-27]. We

discovered that the pharyngeal arch microenvironment is enriched in the ECM

glycoprotein fibronectin (Fn1) both at the mRNA and protein levels [28]. Fn1 is highly

expressed in the pharyngeal endoderm, ectoderm, endothelium, and the second heart

field (SHF) mesoderm between E8.5 and E10.5, the period coinciding with the time

when PAAs form [28, 29]. Between E10.5 and E11.5 Fn1 becomes highly upregulated in

the NC-derived cells abutting the 4th PAA endothelium, corresponding with the time

these cells differentiate into VSMCs. Our previous studies demonstrated that local

depletion of Fn1 in the pharyngeal microenvironment using the Isl1[Cre] knockin mice or in

the NC-derived cells, using a variety of NC-expressing Cre lines, resulted in the I-AAB

and RERSA [29, 30]. However, mechanistically, I-AAB in these mutants had distinct

cellular etiology: ablation of Fn1 in using the Isl1^{Cre} knockin mice led to defective

formation of the 4th PAAs [29], while the ablation of Fn1 in the NC resulted in the

regression of originally well-formed 4th PAAs [31].

Integrins are a major class of transmembrane receptors that engage in signal

transduction upon binding ECM proteins. Integrins are heterodimers of α and β chains.

There are 18 α and 8 β subunits encoded by mammalian genomes, giving rise to 24

different $\alpha\beta$ combinations [32]. Integrin α5 complexes with integrin β1, forming the integrin

α5β1 heterodimer [33]. Integrin α5β1 binds the ECM glycoprotein fibronectin (Fn1), and

regulates Fn1 assembly *in vivo* [34]. Phenotypes resulting from either global or cell-type-

specific ablations of integrin α5 (MGI gene symbol: Itga5) or Fn1 in mice are similar [26,

28, 29, 31, 34-41], indicating that integrin α5β1 is a major Fn1 signal transducer *in vivo*.

Previously, we demonstrated that the expression of integrin α5β1 and Fn1 in the Isl1

lineages was required for the formation of the 4th PAA and the deletion of either integrin

α5 or Fn1 in using the Isl1^{Cre} knockin strain resulted in IAA-B [29]. To understand the

mechanisms by which integrin α5β1 and Fn1 regulate AAA development, we analyzed

SHF and endothelial cell dynamics in integrin α5$^{f/-}$; Isl1^{Cre} and Fn1$^{f/-}$; Isl1^{Cre} mutants

during PAA formation and remodeling, spanning embryonic days (E) E9.5 - E11.5 of

development. Our studies point to the essential roles of cell-ECM interactions mediated

by integrin α5β1 and Fn1 at multiple stages of PAA formation and remodeling.

Methods

Animals All experimental procedures were approved by the Institutional Animal Care

and Use Committee of Rutgers University and conducted in accordance with the

Federal guidelines for the humane care of animals.

Tamoxifen injections *Isl1^MerCreMer* knockin mice [42] and Mef2C-AHF-DreERT2

transgenic mice [43] were used for temporal labeling of vascular progenitors in the SHF.

Tamoxifen was dissolved either in corn oil or in sesame oil at the concentration of 10

mg/ml. Labeling was done by injecting 300 μl of stock solution into pregnant females at

multiple time points specified in the legend to Fig. 1. E0.5 was designated to be at noon

on the day when the vaginal plug was found.

Whole Mount Immunofluorescence staining Labeling with BrdU, TUNEL, and

staining with antibodies were performed as described [29], and analyzed using IMARIS

(Bitplane, USA) [9, 44]. Detailed procedures for staining, analysis and cell quantification is

described in [44].

Statistics Statistical analyses were performed using Prism 8 software version 8.4.3.

Specific statistical tests are indicated in figure legends.

Results

SHF contributes harbors PAA progenitors between E7.5 and E9.5. Previous work

from our lab demonstrated that in the mouse, the majority of PAA endothelium is

derived from the SHF, derived from either Mef2C-AHF-Cre- or Isl1^Cre- expressing

mesodermal lineages [9]. To define the temporal window during which the SHF

mesoderm harbors endothelial progenitors of the PAAs, we used *Isl1^MerCreMer* knockin

mice [42] and Mef2C-AHF-DreERT2 transgenic mice [43] combined with pulses of tamoxifen

to lineage-label the SHF mesoderm at different developmental times (Fig. 1). Tamoxifen

was injected at discrete time points between E6.75 – E9.75, and embryos were

dissected at E10.5 and stained to detect lineage labeling in the pharyngeal arches.

Entire pharyngeal regions were imaged using confocal microscopy to quantify the

contribution of lineage-labeled cells to the PAA endothelium (Fig. 1, panels A-A2). The

expression of VEGFR2 and ERG were used to mark EC cell membrane and nuclei [45].

The labeling of the cardiac outflow tract and the right ventricle using *Isl1^MerCreMer /+* mice

was evident at all stages tested, indicating that our labeling technique was consistent

with previous studies (data not shown) [42]. Myocardial cells derived from the SHF are

labeled when tamoxifen is injected as early as E6.5 in *Isl1^MerCreMer* knockin mice [42],

however no PAA ECs were labeled when tamoxifen was injected at E6.75 in this strain

(Fig. 1B) or at E7.25 in Mef2C-AHF-DreERT2 transgenic strain (Fig. 1C), suggesting

that PAA EC progenitors arise later in the SHF relative to cardiomyocyte progenitors.

The peak labeling of the PAA endothelium occurred when tamoxifen was injected at

E7.25 in *Isl1^MerCreMer* strain (Fig. 1B) and at E8.0 in Mef2C-AHF-DreERT2 strain (Fig.

1C). While tamoxifen injection into *Isl1^MerCreMer* resulted in sparse labeling of PAA ECs,

the injection of tamoxifen into Mef2C-AHF-DreERT2 transgenic mice led to the labeling

of a much larger proportion of ECs in the PAAs (compare Fig. 1B with Fig. 1C). These

differences likely reflect that the MerCreMer transgene is present in a single copy as it is

knocked into the *Isl1* locus [42], while Mef2C-AHF-DreERT2 is a transgenic strain

containing multiple copies of the Mef2C-AHF-DreERT2 transgene [43]. In addition, the

expression of *Is1* is downregulated commensurate with endothelial differentiation [46].

Thus, potentially low levels of *MerCreMer* expression in EC precursors could have

resulted in low labeling of endothelial progenitors in *Isl1^{MerCreMer}* mice relative to Mef2C-

AHF-DreERT2 strain. The difference in the timing of peak EC labeling in the PAAs

between *Isl1^{MerCreMer}* and Mef2C-AHF-DreERT2 strains is likely due to the earlier onset

of *Isl1* expression compared with the expression of the MEF2C-AHF-DreERT2

transgene; in fact, Isl1 regulates the expression of Mef2C and the activation of the

Mef2C-AHF enhancer [47, 48]. Correspondingly, our experiments demonstrate that the

peak endothelial labeling of PAAs in *Isl1^{MerCreMer}* strain precedes that of Mef2C-Dre-

ERT2 strain by 18 hours (compare Fig. 1B with Fig. 1C). Interestingly, the accrual of

SHF-derived ECs into the 4th arch continues past E8.5 as more SHF-derived cells are

labeled in the 4th PAAs than in the 3rd and 6th when tamoxifen is injected at E8.5 and

E9.5 (Fig. 1B1, 1C1). Thus, our labeling experiments show that the SHF mesoderm

harbors PAA endothelial progenitors between approximately E7.5 and E9.5 of

embryonic development.

To analyze the contribution of the SHF to the PAA endothelium quantitatively and to

compare two mouse strains commonly used to label the SHF, we imaged the entire

pharyngeal arch region corresponding to arches 3, 4, and 6, and quantified the

proportion of SHF-lineage labeled ECs in the PAAs from E10.5 embryos derived from

Isl1^{Cre} knockin and Mef2C-AHF-Cre transgenic lines (Fig. 2). The majority of SHF-

derived cells in the pharyngeal arches 3 – 6 are in the endothelium at 37somites, as

seen in sections through the pharyngeal arch region (Fig. 2A – B). Each PAA is

comprised of a similar number of ECs (Fig. 2C). However, there were differences in

PAA labeling among embryos isolated from Isl1^{Cre} and Mef2C-AHF-Cre mice (Fig. 2D,

E). In the constitutive *Isl1^{Cre}* knockin strain, the SHF contribution to the 3rd and 4th PAA

endothelium was 79$\pm$6% and 77$\pm$10%, respectively, and 57$\pm$12% to the 6th PAA (Fig.

2D). While the SHF contribution to the 3rd PAA was 45$\pm$8% in MEF2C-AHF-Cre

transgenic line, which is significantly different from *Isl1^{Cre}* knockin strain (p<10^{-5}, one-

way ANOVA with Tukey's correction for multiple testing). The SHF contribution to the

PAA endothelium of the 4th and 6th PAAs were similar between the two strains (p>0.2,

one-way ANOVA with Tukey's correction for multiple testing). The difference in the

contribution of the SHF to the 3rd PAA between the two strains likely reflects the earlier

onset of Cre expression in the *Isl1^{Cre}* knockin strain relative to MEF2C-AHF-Cre

transgenic line [47]. These data suggest that about half of the 3rd PAA progenitors arise

and leave the SHF prior to the activation of Mef2C-AHF-Cre. These data also indicate

that the deletion of one Isl1 allele, as in the *Isl1^{Cre}* knockin strain, does not impair the

contribution of the SHF to the PAA endothelium. In summary, our data show that the 4th

PAAs differ from the 3rd and the 6th PAAs in the timing during which SHF cells are

added, and differ from the 6th PAA in the proportion of SHF-derived cells.

Cell-ECM interactions mediated by integrin $\alpha5\beta1$ specifically regulate the accrual

of SHF-derived cells into pharyngeal region. Studies described above together with

our previous work [9] have established a framework for the analyses of EC dynamics and

their genetic regulation during the morphogenesis of AAA and its major branches. Our

previous studies demonstrated that the deletion of either integrin $\alpha5$ or Fn1 in the Isl1

lineages resulted in the defective formation of the 4th PAAs at E10.5, and consequently,

IAA-B and retro-esophageal right subclavian artery (RERSA), in these mutants [29]. I-AAB

and RERSA are anomalies resulting from defective morphogenesis of the left and right

4th PAAs, respectively [1, 3]. To determine the mechanisms by which integrin $\alpha 5\beta 1$ and

Fn1 regulate the formation of the 4th PAAs, we analyzed PAA development at distinct

stages of embryonic development using whole-mount immunofluorescence followed by

quantitative analyses of SHF-derived populations and their dynamics.

PAAs form through the coalescence of pharyngeal arch EC plexus [9, 10]. All pharyngeal

arch ECs are located within a plexus of small blood vessels at E9.5. At E10.5 (33 – 34

somite stage), 50% of the 4th arch endothelium is found within the PAA (the vessel

surfaced in green in (Fig. 3B, C) and 50% is in the plexus (pink in Fig. 3B, C) [9]. About

50% of integrin $\alpha 5^{f/-}$; Isl1^{Cre} mutants have defective 4th PAAs, and consequently, 50% of

these mutants develop IAA-B and RERSA [29] . We found that 4th PAA is absent in 50%

of mutants at 32 – 34 somites (Fig. 3D – F). Instead, the endothelium in the 4th arches is

in the form of a plexus of small blood vessels (marked in pink in Fig. 3E, F). A small 4th

PAA eventually formed in these mutants by 36 – 39 somites (Fig. 3J, marked in green in

Fig. 3K, L; compare with the 4th PAA surfaced in green in control Fig. 3G-I). Similarly,

the formation of the 4th PAA was delayed in Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants (Sup. Fig. 1). This

defect was specific to the 4th PAA, as the 3rd and 6th PAAs formed normally in the

mutants (vessels surfaced in white and red in Fig. 3). The incidence of IAA-B and

RERSA is 50% in integrin $\alpha 5^{f/-}$; Isl1^{Cre} and Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants, which is the same as

the incidence of defective 4th PAAs at E10.5 [29]. Therefore, we further investigated the

mechanisms by which integrin $\alpha 5\beta 1$ and Fn1 regulate the formation of the 4th PAAs.

We hypothesized that the defective formation of the 4th PAAs in our mutants could be

due to insufficient EC numbers, defective EC proliferation, or survival. To test these

hypotheses, we evaluated total EC numbers in the 4th pharyngeal arches of controls

and mutants. To quantify EC number, we stained E10.5 embryos with the antibodies to

ERG, a transcription factor enriched in the endothelia and either VEGFR2 or Pecam 1,

expressed on EC surface, as described [44]. These experiments showed that integrin $\alpha 5^{f/-}$

; Isl1^{Cre} and Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants had decreased total number of ECs in the 4th arches

at 32 – 33 somites relative to controls (Fig. 3M and Sup. Fig. 1A-C). Despite this

decrease in EC numbers, the size of the 4th arches, the tissues within which PAAs form,

was not affected (Fig. 3N). EC proliferation in the 4th arch was also not affected in the

mutants (Fig. 3O), and neither was cell survival (Sup. Fig. 2). Thus, EC deficiency in the

4th pharyngeal arches of the mutants was not due to defective cell proliferation or

survival. The majority of VEGFR2$^+$ cells in the pharyngeal arches of E9.5 embryos were

labeled with GFP (Sup. Fig. 3A – A2, B – B2), indicating that SHF cells in the

pharyngeal region of the mutants were not impaired in the acquisition of EC fate.

VEGFR2 is expressed the 4th pharyngeal arch endothelium at E9.5, which is a day

earlier than Pecam 1 [10]. To determine whether the maturation of pharyngeal arch ECs

was affected in the mutants at E10.5, we co-stained embryos with antibodies to

VEGFR2 and Pecam 1. Despite defective 4th PAA formation, all VEGFR2$^+$ cells in

pharyngeal arches of the mutants also expressed Pecam1 at E10.5 (Sup. Fig. 3C, D,

C1, D1), ruling out maturation as a cause for decreased EC numbers in the 4th

pharyngeal arch.

Since the maturation, proliferation, and survival of ECs were not affected in our mutants,

we tested the hypothesis that defective recruitment of progenitor cells into the

pharyngeal arches was the cause for decreased EC numbers in the 4th arch. As we

established before, the majority of PAA endothelium arises from the SHF (Fig. 2D, E

and [9], and the accrual of SHF-derived cells into the pharyngeal arches is mostly

complete by E9.5 (Fig. 1B-C). To quantify the number of SHF-derived cells in the

pharyngeal mesenchyme, we used ROSA^{nT-nG} reporter mice, in which nuclear

localization sequences were fused with tdTomato and EGFP, leading to the expression

nuclear-localized EGFP upon Cre-induced recombination. We found that

the deletion of integrin $\alpha 5$ in the Isl1 lineages impaired the accrual of SHF cells into the

pharyngeal region (Fig. 4A-B), while the accrual of SHF-derived cells into the heart was

not affected (Fig. 4C).

Splanchnic mesoderm within the dorsal pericardial wall harbors both cardiac and

vascular progenitors. To test whether the deficiency in the pharyngeal SHF-derived

mesoderm was due to the decrease in SHF cells numbers in the splanchnic mesoderm,

we used IMARIS to surface cells within this region and quantified the number of GFP$^+$

cells (see Sup. Fig. 4 for details on surfacing). These experiments showed that the

number of GFP$^+$ cells in the splanchnic mesoderm within the dorsal pericardial wall was

similar between controls and mutants (Fig. 4D). Next, we computed the proportion of

GFP$^+$ cells in the pharyngeal mesenchyme or in the heart relative to the number of

GFP$^+$ cells in the splanchnic mesoderm. While the latter ratio was not affected in the

mutants (Fig. 4E), the former was significantly decreased in the mutants (Fig. 4F),

suggesting that there is a defect either in the specification of pharyngeal progenitors in

the SHF or in their exit from the SHF. Taken together, these experiments indicate that

ECM microenvironment sensed through the signaling by integrin $\alpha5\beta1$ is important for

the accrual of the SHF-derived mesoderm to the pharyngeal arches (Model in Fig. 8,

PAA formation panel A1).

Integrin $\alpha5\beta1$ and fibronectin regulate the remodeling of pharyngeal plexus into

the 4th PAAs independently of EC numbers. Interestingly, the number of SHF-derived

cells and ECs in the mutants recovered by the 34-35 somite stage, and was similar to

that of controls (Fig. 5A). Total number of GFP$^+$ cells also recovered (Fig. 5B). The

percentage of GFP$^+$ ECs in the pharyngeal arches of controls and mutants were

comparable (Fig. 5C), indicating that the recovery was not due to the recruitment of ECs

from an alternative mesodermal source. The recovery of pharyngeal EC numbers was

likely mediated through the proliferation of SHF-derived ECs. The basis for this

conclusion is the following. The proliferation index of pharyngeal arch ECs was

unaltered in the mutants (Fig. 3O), and the proliferation index of ECs in the pharyngeal

plexus is 2-fold higher than that of PAA ECs, both in controls and in mutants (Fig. 3O,

plexus). Since the proportion of ECs in the pharyngeal plexus is higher in the mutants

than in controls (Sup. Fig 1D), the higher proliferation index of plexus ECsin the mutants

is likely responsible for EC recovery. Our quantitative analyses indicate that PAA

formation phenotypes in integrin $\alpha5^{f/-}$; Isl1$^{Cre/+}$ and Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants are

indistinguishable from one another (Sup. Fig. 1), suggesting that integrin $\alpha 5\beta 1$ is a

major receptor transducing Fn1 signals within the pharyngeal microenvironment.

Despite the recovery of EC numbers (Fig. 5A), PAAs remained thin in integrin $\alpha 5^{f/-}$;

Isl1^{Cre} and Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants (Fig. 3G – L), and there was 2 – 3-fold decrease in

the proportion of pharyngeal arch ECs in the 4th PAAs at all stages analyzed at E10.5

(Fig. 6A). The size of the 4th PAA increases between 32 – 39 somites, as more ECs are

added to the PAA from the plexus (Sup. Fig. 5), and is reflected in the percent of

pharyngeal arch ECs in the PAA [9]. In controls, plexus ECs in the 4th arch begin

coalescing into the PAA when embryos reach between 31 and 32 somites [9] (Sup. Fig.

5). These rearrangements result in an initially thin 4th PAAs, in which approximately

50% of the pharyngeal arch ECs are in the plexus and 50% in the PAA at 32 – 34

somite stage [9]. As the development proceeds, by 36-39 somite stage, > 60% of the 4th

pharyngeal arch endothelium becomes incorporated into the 4th PAA [9]. Thus, the

percentage of the pharyngeal arch endothelium in the 4th PAA can be taken as a

measure of PAA formation. The higher the proportion, the larger the PAA [9].

To understand the mechanisms by which integrin $\alpha 5\beta 1$ and Fn1 regulate the

remodeling of the uniform endothelial plexus into the PAA in the 4th arch, we examined

EC dynamics in control and mutant embryos at three time points, corresponding with 32

– 33 somites, 34 – 35 somites, and 36 – 39 somites. These stages span about 6 hours

on the 10th day of mouse embryonic development. The formation of the 4th PAAs lagged

in mutants relative to controls at all time points tested during E10.5 (Fig. 6A and Sup

Fig. 1D, E), and 7 of the 16 embryos analyzed contained only a plexus of ECs and

lacked the 4th PAAs at the 32 – 34 somite stage (Sup. Fig. 1E), a stage at which over

50% of the 4th arch endothelium in controls is located within the 4th PAAs [9] (Fig. 6A and

Sup Fig. 1E).

Since mutant embryos had fewer ECs in the 4th pharyngeal arches compared with

controls prior to the 36th somite stage, we performed correlation analyses to test the

hypothesis that the formation of the 4th PAAs depended on the total EC number or EC

density in the 4th pharyngeal arches. As described above, the percentage of pharyngeal

arch ECs in the PAA relative to the plexus can be taken as a measure of PAA formation

(Sup. Fig. 5) [9]. Thus, for these analyses, we quantified EC numbers in control embryos

isolated between 32 to 39 somite stages and plotted them against the percent of ECs in

the 4th PAAs (Fig. 6B). Despite the sharp, over a 3-fold increase in the number of ECs in

the 4th arches between these stages [9], the formation of the 4th PAAs was independent

of the total EC number in the 4th pharyngeal arch tissue (Fig. 6B) or EC density (Fig.

6C) in controls throughout the 10th day of embryonic development. Similarly, correlation

analysis of PAA formation in the mutants with defective (thin) and normal 4th PAAs,

showed that similar to controls, the rearrangement of plexus ECs into the PAA did not

depend on the number of total number of ECs in the 4th pharyngeal arches of mutants

(Fig. 6D).

Next, we compared PAA formation in controls and mutants that had a similar number of

ECs in the 4th pharyngeal arches (Fig. 6E). These analyses showed that in groups of

mutant and control embryos with a similar number of ECs, the percent of ECs in the

PAAs was lower in the mutants (boxes in Fig. 6E). These data indicate that the

reorganization of the plexus ECs into the PAA in the 4th pharyngeal arch does not

depend on the EC number at E10.5, and is regulated by factors extrinsic to the

pharyngeal arch endothelium. In summary, our studies indicate that during the 10th day

of embryonic development, cell – ECM interactions mediated by integrin $\alpha5\beta1$ and Fn1

are essential for the remodeling of the initially uniform vascular plexus into the PAA in

the 4th pharyngeal arches (Model in Fig. 8, PAA formation panel A2).

378 The expression of integrin $\alpha5$ in the Isl1 lineage is required for the differentiation

379 of neural crest cells into vascular smooth muscle cells.

In the Tbx1[+/-] mouse model of 22q11 deletion syndrome, PAA formation recovers in 50

– 68% of the mutant mice [49, 50]. To determine whether the rearrangement of the

endothelial plexus in the 4th arch was blocked or delayed, we examined E11.5 embryos.

The incidence of IAA-B and RERSA in integrin $\alpha5$[f/-]; Isl1[Cre] mutants is 50%, which is the

same as the incidence of defective 4th PAA formation. Therefore, we expected to find

absent or thin 4th PAAs in the mutants at E11.5. Contrary to our expectations, the

formation of the 4th PAAs recovered in the mutants by E11.5, and PAA perimeters in the

mutants were comparable with controls (Fig. 7A, n=8). Consistent with the recovery of

SHF-derived ECs numbers by 33 – 35s, PAA ECs were GFP[+] cells in the mutants as in

controls (compare Fig. 7C1 with 7D1, arrowheads). Regression of left 4th PAAs results

in IAA-B and regression of the right 4th results in RERSA [51, 52]. Since 50% of *integrin*

$\alpha5$[flox/-]; Isl1[Cre] mutants develop 4th arch artery defects, such as IAA-B and RERSA [29],

these data indicated that the 4th PAAs eventually regress in the mutants. Arch artery

regression is commonly caused by the defective differentiation of neural crest cells

surrounding the PAA endothelium into vascular smooth muscle cells, VSMCs [52-57]. In

pharyngeal arches, VSMCs exclusively arise from NC-derived cells [49, 58, 59]. To

determine whether the differentiation of NC-derived cells into VSMCs was affected in

our mutants, we analyzed VSMC differentiation in the pharyngeal arches. For these

experiments, we calculated the fraction of vessel perimeter covered by alpha smooth

muscle actin (αSMA)-expressing cells, using previously-developed methodology [31]. We

found that the differentiation of NC-derived cells into VSMCs was severely diminished

around the PAAs in the mutants (quantified in Fig. 7B; compare sections in Fig. 7C, D,

magnified in Fig. 7C2, D2; zoom-out panels are in Sup. Fig. 6). The decrease in αSMA

expression was not due to NC cell death (Sup. Fig. 2).

Even though, the *Isl1* lineage marks a subset NC-derived cells [60], Isl1 protein is not

expressed in NC-lineage cells in the pharyngeal arches, and Isl1 lineage does not label

cells adjacent to the PAA endothelium (Fig. 7C1, D1) [29]. Moreover, comparison of NC

lineage (Fig. 7E – E4) and Isl1 lineage maps at E11.5 demonstrates that αSMA

expression coincides with the NC lineage (Fig. 7E2), but not with Isl1 lineage-labeled

cells (arrows in Fig. 7C1 and C2 point to αSMA-expressing cells; arrowheads point to

GFP⁺ PAA endothelium). These studies indicate that the expression of integrin α5 in the

Isl1 lineage(s) regulates the differentiation of NC cells into VSMCs in a non-cell

autonomous manner. These results are consistent with our previous experiments

demonstrating that the expression of integrin α5 in the *Mesp1* lineage marking the

anterior mesoderm regulates the differentiation of NC cells into VSMCs around the 4th

PAA [59]. Since the deletion of integrin α5 in the *Mesp1* lineage does not result in

defective or delayed PAA formation [59], these data taken together, indicate that the

defect in VSMC differentiation in *integrin $\alpha5^{flox/-}$; Isl1^{Cre}* mutants is not merely due to the

delayed accrual of arch artery endothelium, or delayed remodeling of the vascular

plexus into the PAA. In summary, our studies also indicate that in addition to regulating

4th PAA formation, integrin α5 expressed in the *Isl1* lineages plays an independent role

in arch artery morphogenesis, namely in the differentiation of NC-derived cells into

VSMCs (Fig. 8A).

The differentiation of NC into VSMCs is orchestrated in part by a relay of Notch

signaling transduced from the PAA endothelium to the surrounding layers of NC-derived

cells [56]. The activation of Notch signaling in the NC is required for the differentiation of

NCs into VSMCs [52, 56]. We demonstrated that this pathway was regulated by the

expression of integrin α5 and fibronectin specifically by NC-derived cells at E11.5 [31]. To

test the possibility that the expression of integrin α5 in the *Isl1* lineages regulates the

lateral propagation of Notch from the PAA endothelium to the adjacent NC-derived cells,

we stained control and mutant sections with an antibody to Notch Intracellular Domain

(NICD), an activated form of Notch. However, Notch signaling was activated

comparably in controls and mutants, despite the severe deficiency in the differentiation

of NC cells into VSMCs in the mutants (compare Fig. 7C2 – C4 with Fig. 7D2 – D4,

arrows). These experiments indicate that the expression of integrin α5 in the pharyngeal

arch mesoderm regulates the differentiation of NC cells into VSMCs independently of

Notch. Furthermore, these experiments indicate that while the activation of Notch is

necessary for the differentiation of NC-derived cells into VSMCs, it is not sufficient.

Taken together, with our previous work [31, 59], studies in this manuscript demonstrate that

cell-ECM interactions regulated by integrin α5β1 and Fn1 play multiple, pleiotropic, and

stage-specific functions during the morphogenesis of the 4th PAAs (Fig. 8).

441 **Combinatorial expression of integrin α5 and fibronectin from multiple lineages in**

442 **the pharynx regulates the formation of the 4th PAAs.**

443 The *Isl1* lineages encompass the mesoderm in the SHF and pharyngeal arches,

444 pharyngeal endoderm, surface ectoderm, and some NC-derived cell populations,

445 although not the NC in the pharyngeal arches [29, 42, 59, 60]. Our previous studies indicated

446 that the combined expression of integrin α5β1 or Fn1 in the surface ectoderm and the

447 NC was not required for the formation of the 4th PAAs [29, 31]. However, even though PAA

448 formation occurred normally in these mice, the 4th PAAs regressed later due to defects

449 in the differentiation of NC-derived cells into VSMCs, resulting in RERSA and IAA-B [31]

450 (Fig. 8). The expression of either integrin α5β1 or Fn1 in the SHF lineage marked by the

451 expression of the Mef2C-AHF-Cre transgene is also not required for PAA formation

452 (Sup. Tables 1 and 2), indicating that the expression of integrin α5β1 or Fn1 in the SHF

453 alone is not required for cardiovascular development. Consistent with these findings, the

454 expression of integrin α5β1 in the *Mesp1* lineage or in the endothelium was not required

455 for PAA formation [59, 61] (Fig. 8). Instead, the expression of integrin α5β1 in the Mesp1

456 lineage was required for PAA stability, and the deletion of integrin α5 in *Mesp1* lineage

457 which includes the PAA endothelium resulted in IAA-B and RERSA (Fig. 8) [59, 61].

458 The difference in the phenotypes resulting from the deletion of integrin α5 using Mef2C-

459 AHF-Cre and Mesp1[Cre] are likely the result of differences in the timing of Cre expression

460 (e.g. the later onset of Mef2C-AHF-Cre may have allowed the perdurance of integrin

461 α5β1 protein through the stages where it's required for mesoderm-NC interactions).

462 Alternatively, the expression of integrin α5β1 in Mesp1 lineage-derived mesodermal

cells prior to E8.5 is important for the regulation of NC cell fate in the pharyngeal arches

[59].

Lastly, we tested whether the expression of integrin α5 in the endoderm regulated PAA

formation. For these experiments, we used the constitutive Sox17[2A-iCre] knockin mouse

line, in which Cre is expressed in the endoderm and pharyngeal arch ECs (Sup. Fig. 7A

– A4) [62]. However, PAAs formed normally in $\alpha5^{flox/-}$; Sox17[2A-iCre] mutants (Sup. Fig. 7B,

B1, C, C1). Together, these data indicate that combinatorial expression of integrin α5

and Fn1 in the Isl1 lineages is necessary for the proper formation of the 4th PAAs (Fig.

8).

Discussion

Proper development of the 4th PAAs is central to the ability of a newborn to survive and

thrive (Karunamuni et al., 2014; Moon, 2008). The formation of the 4th pair of the PAAs

is regulated by a number of genes including *Tbx1, Pax9, Gbx2, Fgf8, Crkl, PlexinD1,*

and Nrp1, e.g., [63-67]. However, cellular mechanisms by which these genes mediate PAA

formation are not well-understood. Unraveling the dynamics of EC progenitors and their

descendants during PAAs formation is vital to understanding the genetic and cellular

mechanisms regulating PAA formation and how they are altered in congenital heart

disease.

In this manuscript, we have demonstrated that the SHF is the primary source of the

PAA endothelium and that the majority of endothelial progenitors giving rise to the PAAs

are already present in the SHF by E7.5. PAA progenitors exit the SHF and contribute to

the PAAs over a span of about 2 days, from E7.5 to E9.5.

Lineage labeling using constitutive Cre lines Isl1^{Cre} and Mef2C-AHF-Cre led to similar

labeling of the PAA endothelium, with the exception of the 3rd PAA, which is labeled

50% more efficiently when Isl1^{Cre} line of mice is used. This difference likely reflects the

timing of Cre expression in Isl1^{Cre} and Mef2C-AHF-Cre strains, with Mef2C-AHF-Cre

lagging by about a day [42, 48, 68]. This suggests that about half of the endothelial

progenitors of the 3rd PAA have exited the SHF by the time Mef2C-AHF-Cre is

expressed. Our fate mapping studies show that there are differences in the timing and

the extent of SHF contribution to the PAAs. In particular, if one were to use Mef2C-AHF-

Cre to generate mutations, the 4th PAAs could be more affected than the 3rd and the 6th

because in the MEf2C-AHF-Cre strain, the contribution of the SHF lineage-labeled ECs

to the 4th PAA endothelium is the highest.

By using whole-mount imaging and quantitative analyses of EC populations in the

pharyngeal arches, we previously demonstrated that the morphogenesis of the 4th PAAs

occurs gradually throughout the 10th day of the embryonic development and entails a

rapid accumulation of ECs: endothelial population in the 4th pharyngeal arch increases

more than three-fold in about eight hours of development, from 30 – 39 somites [9]. This

steep increase is unlikely to occur solely due to EC proliferation, and our labeling

experiments show that SHF-derived cells are still being added to the 4th PAA after E9.5.

Our studies show that integrin $\alpha5\beta1$ and Fn1 are important for initial recruitment of SHF-

derived ECs into the 4th pharyngeal arches, and that in the absence of integrin $\alpha5$ or

Fn1 in the Isl1 lineages results in EC deficiency up to 32 – 34 somite stage. Despite the

initial EC deficiency in the 4th arch, EC numbers recover in integrin $\alpha5^{f/-}$; Isl1$^{Cre/+}$ and

Fn1$^{f/-}$; Isl1$^{Cre/+}$ mutants by the 34 – 35 somite stage. We demonstrate that the recovery

of EC cell numbers in the pharyngeal arches is not due to compensation from an

alternative endothelial source. Instead, we show that the proliferation index of plexus

endothelium is 2-fold higher than that of ECs in the PAA (Fig. 3O). This difference in the

proliferation index is maintained in the mutants (Fig. 3O). We hypothesize that since the

majority of ECs is in the plexus in the mutants at 32 – 33 somites, their proliferative

advantage over ECs in the PAA allows the EC number in the mutant arches to recover

by the end of E10.5.

However, in spite of the recovery of EC populations in the 4th arches, the 4th PAAs were

either thin or absent in 50% of all the 4th arches by 36 – 39 somite stages [29]. Our

regression analysis showed that the rearrangement of the 4th pharyngeal arch ECs into

the PAA was not dependent on the number or density of ECs in the 4th arch. These data

suggest that the remodeling of the uniform endothelial plexus into the PAA in the 4th

arch is mediated by factors extrinsic to the endothelium. The disruption of the

remodeling in our mutants indicates an essential role for cell – ECM interactions in this

process.

The *Isl1* lineage encompasses multiple cell types within the pharynx including

pharyngeal epithelia, mesoderm, and a population of NC cells in the cardiac outflow

tract [60, 68]. Pharyngeal endoderm and the ectoderm are important signaling centers

regulating intercellular communications among the germ layers composing the arches,

the endoderm, mesoderm, surface ectoderm and the neural crest, mediating the

morphogenesis of cardiopharyngeal organs and structures [27, 69, 70]. Modulation of the

extracellular microenvironment within the pharynx is essential for the development of

the heart, the AAA and its branches [29, 31, 59, 63, 64, 71-81]. The expression of *Fn1*, an

essential ECM glycoprotein, is highly enriched in the pharyngeal epithelia and Fn1

protein is enriched in the pharyngeal arches 3 – 6 [28, 29]. Our studies show that the

expression of Fn1 in the Isl1 lineages is important for the formation of the 4th PAAs,

while Fn1 expression in the NC regulates PAA stability [29, 31] (Fig. 8).

In this manuscript, we investigated the tissues wherein signaling by Fn1 is important for

PAA formation. Integrin $\alpha 5\beta 1$ is a major Fn1 receptor during embryogenesis [28-30, 34, 38,

39, 41], and the deletion of integrin $\alpha 5$ or Fn1 in the Isl1 lineages results in identical

phenotypes [29]. To determine the cell type(s) in which signaling by Fn1 regulates PAA

formation, we ablated integrin $\alpha 5$ in each of the tissues comprising Isl1 lineage

individually or in combination. The deletion of integrin $\alpha 5$ in the SHF (Mef2C-AHF-Cre

strain), the entire anterior mesoderm (Mesp1^{Cre}), the NC (Wnt1-Cre2, P3Pro-Cre), the

NC and surface ectoderm (TFAP2$\alpha^{IresCre}$), or the endoderm and endothelia (Sox17^{2A-}

^{iCre}) resulted in normal PAA formation (this study and [29, 31, 59]). Therefore, we conclude

that combinatorial signaling by integrin $\alpha5\beta1$ from pharyngeal endoderm, mesoderm,

and the surface ectoderm is essential to mediate the formation of the 4th PAAs. While

signaling in the mesoderm and the neural crest is important for PAA stability (Fig. 8).

The PAAs form within the neural crest-derived pharyngeal mesenchyme and the PAA

endothelium induces the differentiation of the adjacent NC-derived cells into VSMCs [56].

Despite the initial delay in the formation of the 4th PAAs, the size of PAAs in integrin $\alpha5^{f/-}$

; Isl1[Cre/+] mutants has recovered by E11.5. At this time, we observed a profound

deficiency in the expression of αSMA by NC-derived cells around the PAAs in the

mutants. Deficiency in VSMC differentiation causes vessel regression [31, 52, 57, 82, 83],

consistent with our findings that integrin $\alpha5^{f/-}$; Isl1[Cre/+] and Fn1[f/-]; Isl1[Cre/+] mutants

develop IAA-B and RERSA, defects that are caused by the aberrant morphogenesis of

the left and right 4th PAAs, respectively [29]. Our previous studies using integrin $\alpha5^{f/-}$;

Mesp1[Cre/+] mice demonstrated that the expression of integrin $\alpha5$ in the mesoderm

regulates NC differentiation into VSMCs without affecting PAA formation, and integrin

$\alpha5^{f/-}$; Mesp1[Cre/+] mice develop IAA-B and RERSA [59] (Fig. 8). Thus, the roles of integrin

$\alpha5\beta1$ and Fn1 in the formation of the 4th PAAs are separate from their roles in the

differentiation of NC-derived cells into VSCMs [31].

Mechanisms that lead to IAA-B are complex but generally arise due to either of the

following two broad categories of defects: a) defects in the formation of the left 4th PAA

or b) defects in the stability of an otherwise well-formed 4th PAA. NC ablation studies in

chick and genetic manipulation of the neural crest demonstrate that NC is not required

for PAA formation [51, 52]. Even in the extreme case of neural crest ablation, PAAs form [51].

However, defective differentiation of NC-derived cells into VSMCs leads to PAA

regression resulting in various malformations in the aortic arch and its branches,

including IAA-B and RERSA [31, 52, 82]. Our studies show that the expression of integrin

$\alpha5\beta1$ in the pharyngeal mesoderm and the NC are required for NC-to-VSMC

differentiation, and the expression of integrin $\alpha5\beta1$ in either of these lineages alone is

not sufficient for this process [31, 59].

Defects in the formation of the 4th PAAs often occur in conjunction with 22q11 deletion

syndromes [84]. Cumulatively, four prospective studies found that between 40 and 90% of

interrupted aortic arch type B (IAA-B) cases diagnosed in fetuses, neonates, and

children can be attributed to deletions in the 22q11 region [85]. Studies using *Tbx1*[+/-] mice

that model 22q11 deletion syndrome indicated that defective formation of the left 4th

PAA underlies IAA-B in these patients [65, 86, 87]. Intriguingly, several independent

publications demonstrated that *Tbx1* regulates the expression of integrins and

extracellular matrix (ECM) components, and showed that defects in cell-ECM

interactions downstream of *Tbx1* precede pathological sequelae and cardiovascular

defects in *Tbx1* mutants [71-73]. Interestingly, about 50% of Tbx1[+/-] mice recover from the

initial defect in PAA formation, and are viable and fertile [50]; However, this recovery can

be impeded by the reduction in the expression of Fn1 [49]. Thus, alterations in cell-ECM

interactions and pharyngeal ECM microenvironment may underlie lethal AAA defects in

22q11 deletion syndrome downstream of *Tbx1*.

The significance of our work lies in the identification of cellular dynamics regulating PAA

formation and the intricate temporal and cell-type specific roles of cell-ECM interactions

in the regulation of aortic arch morphogenesis at multiple steps of its formation and

remodeling (Fig. 8).

Acknowledgements We thank Richard Hynes, Chenleng Cai, Sylvia Evans, Benoit

Bruneau, Heicko Lickert, and Hongkui Zeng for the gift of mouse strains, and Brianna

Alexander and Nathan Astrof for careful reading of the manuscript.

Sources of Funding This work was supported by the funding from the National Heart,

Lung, and Blood Institute of the NIH R01 HL103920, R01 HL134935, and R21

OD025323-01 to SA, and pre-doctoral fellowship F31HL150949 to AJR.

Disclosures None

Supplemental Materials
Expanded Materials & Methods
Online Figures 1 – 7

 Figure Legends

Figure legends are also included with the figures

Figure1. Endothelial PAA progenitors are arise in the SHF as early as E7.25.

Isl1^{MerCreMer} and Mef2C-AHF-DreERT2 males were mated with the appropriate reporter

females (see Methods). E0.5 was considered to be noon on the day of the vaginal plug.

Tamoxifen was injected at specified times, embryos were dissected at E10.5, and

stained to detect VEGFR2 (blue), ERG (red), or tdTomato (orange). **A.** Sagittal view and

3D reconstruction through the left pharyngeal region. Inset- 3D reconstruction of PAAs.

A1 – A2. Sagittal optical sections through the embryo shown in **A.** Labeling efficiency

was quantified by calculating the ratio of the number of ERG$^+$ tdTomato$^+$ ECs to the

total number of ERG$^+$ ECs in PAAs using IMARIS spot function. **B.** Highest labeling of

PAA endothelium occurred when tamoxifen was injected at E7.25 in Isl1^{MerCreMer} knockin

mice. **B1.** SHF-derived cells continute to be added the 4th PAA after E9.5. C. Peak

labeling of PAA ECs occurred when tamoxifen was injected at E8.0 in MEF2C-AHF-

DreERT2 strain. **C1.** Injection of tamoxifen at E8.5 led to a more efficient labeling of the

4th PAAs than the 3rd and 6th PAAs.

Figure 2. Majority of PAA ECs are SHF-derived; there are differences in the

contribution of the SHF to the PAA endothelium depending on the strain used.

Mef2C-AHF-Cre; ROSA^{tdTomato} embryos (35 – 37 somites) were stained with antibodies

to VEGFR2 (turquoise) to detect endothelial cells, tdTomato (orange) to detect SHF-

derived cells, and DAPI (blue) to stain cell nuclei. **A – A2.** 3D reconstructions of PAAs

and their connections with the dorsal aorta (dAo) and the aortic sac (Ao S). **B – B2.**

Sagittal optical sections to show the distribution of all SHF-derived cells in the

pharyngeal arches. PAAs 3 – 6 are labeled. Magnifications are the same in all panels.

All scale bars are 100 μm. **C.** The number of VEGFR2$^+$EGR$^+$ cells in the pharyngeal

arches was quantified in 5 E10.5 embryos at 35 – 37 somites using IMARIS. Each dot is

one arch. Red line marks the median. Black lines mark quartiles. Differences among the

three PAA pairs are not significant, p>0.1 by one-way ANOVA with Tukey's correction

for multiple testing. **D – E.** The percentage of VEGFR2$^+$EGR$^+$ cells expressing the Cre

reporter was determined in each PAA (orange bars). Blue bars are the percent of

VEGFR2$^+$EGR$^+$ cells that were not labeled with the Cre reporter. **D.** The use of

constitutive Isl1^{Cre} strain resulted in labeling of more than 80% of ECs in the 3rd and 4th

PAAs. **E.** The use of Mef2C-AHF-Cre strain resulted in a significantly higher labeling of

the 4th PAAs than the 3rd and the 6th. The difference in the labeling efficiency of 6th

PAAs between the two strains was not significant, p> 0.2. All statistical analyses were

performed using one-way ANOVA with Tukey's correction for multiple testing.

Figure 3. Formation of the 4th PAA is delayed in integrin α5$^{flox/-}$; Isl1^{Cre} mutants.

Integrin α5$^{flox/+}$; Isl1^{Cre} control and α5$^{flox/-}$; Isl1^{Cre} mutant embryos were dissected at

different somite stages at E10.5 and stained to detect Pecam1. PAAs are numbered

and somite stages are indicated in the first row. **A, D, G, J.** 3D reconstructions of whole-

mount Pecam 1 staining (light blue). **B, E, H, K.** PAA endothelium in the 3rd, 4th and 6th

arches shown in the row above was surface-rendered white, green and red,

respectively. In addition, the plexus endothelium in the 4th arch was surface-rendered in

pink. **C, F, I, L.** Left side and ventral views of surface-rendered PAAs and the plexus.

Development of the 4th PAAs was specifically affected in the mutants (**E, F**).

Magnification is the same in all panels. Scale bar is 100 μm. **M.** Total number of

endothelial cells was quantified as described in Methods. Mutants have EC deficiency in

the 4th arch as 32 – 33 somites. **N.** The sizes of the 4th arches are comparable between

controls and mutants. **O.** EC proliferation in the PAA and the plexus in the 4th arches

was similar in controls (C) and mutants (M). In all plots, solid lines mark the median,

dashed lines mark the quartiles. Each dot marks one arch. At least 3 mutants and 3

controls were assayed. Statistics were evaluated using 2-tailed, unpaired Student's t

test with Welch's correction for unequal standard deviation between samples.

Figure 4. **The expression of integrin a5 in the Isl1 lineages is required for the**

accrual of SHF-derived cells to the pharyngeal mesenchyme. Control and mutant

embryos carrying one ROSA^{nTnG} reporter allele were dissected at E9.5 (18 – 20 somite

stage) and stained with DAPI and anti-GFP antibodies. Whole embryos were imaged

and the number of GFP$^+$ cells (SHF-derivatives) in the arch mesenchyme, splanchnic

mesoderm, and in the heart was quantified as described in Sup. Fig. 4. **A.** The total

number of SHF cells in the mesenchyme of the 1st and 2nd arches was decreased in the

mutants. **B.** The total number of of GFP$^+$ cells in the pharyngeal mesenchyme

corresponding with the future arches 3 – 6 was decreased in the mutants. The number

of SHF cells in heart (**C**) and the splanchnic mesoderm (**D**) was not affected. **E.** The

proportion of GFP$^+$ cells in the heart relative to GFP$^+$ cells in splanchnic mesoderm was

not affected in the mutants. **F.** The proportion of GFP$^+$ cells in the posterior pharyngeal

mesenchyme relative to the number of GFP$^+$ cells in splanchnic mesoderm was

significantly decreased in the mutants. Each dot marks one embryo, red lines mark

medians, dotted lines mark quartiles; p values were determined using unpaired, 2-tailed

Student's t tests.

Figure 5. Recovery of EC numbers in integrin $\alpha 5^{flox/-}$; Isl1$^{Cre/+}$ mutants. A. Total EC

number has recovered in integrin a5$^{flox/-}$; Isl1$^{Cre/+}$ mutants by the 34th somite stage. **B.**

Total number of SHF-derived mesodermal cells has recovered in the pharyngeal arches

in integrin $\alpha 5^{flox/-}$; Isl1$^{Cre/+}$ mutants by the 34th somite stage. **C.** The fraction of SHF-

derived ECs in pharyngeal arches is comparable among control and mutant embryos.

This fraction was calculated by quantifying the number of GFP$^+$ERG$^+$ cells and dividing

by the total number of ERG$^+$ cells in the entire pharyngeal arches (e.g. ECs in PAA and

plexus were quantified). Statistical significance was evaluated using one-way ANOVA

with Tukey's correction for multiple testing.

Figure 6. Integrin $\alpha 5 b 1$ and Fn1 regulate the remodeling of EC plexus during the

formation of the 4th pharyngeal arch arteries. A. The proportion of ECs in the 4th

PAAs in the mutant is significantly lower than in controls at all stages analyzed at E10.5,

including the stages when the EC population in the 4th pharyngeal arch has recovered in

the mutants; 2-tailed, unpaired Student's t test. **B – C.** Linear regression analyses

indicate the absence of linear correlation between the size of the 4th PAA and EC

number (**B**) or density (**C**). PAA size is expressed as the percentage of pharyngeal arch

endothelial cells in the 4th PAA in control embryos on the y-axis. **D.** Total EC number (x-

axis) from mutants with defective (open symbols) or unaffected 4th PAA (closed

symbols) were plotted against the size of the 4th PAAs, y -axis. Regression analysis

indicated low correlation between these properties. Circles: 32 – 33 somite embryos,

rhombi: 34 – 35 somite embryos, triangles: 36 – 39 somite embryos. **E.** The

rearrangement of the endothelial plexus into the 4th PAAs is defective in mutants

relative to controls with the same number of endothelial cells in the 4th arch (red boxes).

EC – endothelial cell(s). Controls: $\alpha5^{f/+}$; Isl1$^{Cre/+}$ and Fn1$^{f/+}$; Isl1$^{Cre/+}$ embryos; Mutants:

$\alpha5^{f/-}$; Isl1$^{Cre/+}$ and Fn1$^{f/-}$; Isl1$^{Cre/+}$ embryos.

Figure 7. The expression of integrin $\alpha5\beta1$ in the Isl1 lineages regulates the

differentiation of neural crest-derived cells into VSCMs at E11.5 A. PAA perimeter

has recovered in size in the mutants by E11.5. **B.** Smooth muscle coverage of the left

4th and left 6th PAA was deficient in the mutants. **C – D**. Despite defective differentiation

of NC cells into VSMCs, the activation of Notch in the pharyngeal arch mesenchyme

was not altered in the mutants. PAAs are numbered. PAA lumens at E11.5 are derived

from the Isl1^{Cre} lineage (green, arrowheads in **C1** and **D1**). αSMA$^+$ cells are GFP-

negative in Isl1^{Cre} strain (arrows in **C1-C2**). **C2 – D2**. VSMC differentiation assayed by

the expression of alpha smooth muscle actin (αSMA, blue) is specifically affected

around the 4th PAAs in the mutants (compare regions marked by the arrows in **C2** and

D2). The activation of Notch assayed by the expression of NICD is not altered in the

mutants with defective VSCM differentiation (arrows in **C3, C4** and **D3, D4**). **E.** Fate

map using TFAP2$\alpha^{IRESCre}$ shows the location of NC-derived cells in the pharyngeal

arches. Note extensive colonization of the mesenchyme between the endodermal

pouches (endo) by the TFAP2$\alpha^{IRESCre}$ lineage. **E2**. αSMA$^+$ cells are GFP$^+$ in

TFAP2α^{IRESCre} strain. All scale bars are 50 μm. Additional zoom-out views are in Sup.

Fig. 6.

Figure 8. Cell – ECM interactions play essential roles at multiple stages during the

development of the aortic arch and its branches. A. The expression of integrin α5β1

and Fn1 in the Isl1 lineages is required for the formation of the 4$^{\text{th}}$ PAAs. **A1**. A

schematic of Isl1 lineages (green) in the pharynx at E8.5 – E9.5. Green arrows indicate

migration of splanchnic mesoderm cells into the pharyngeal arches. Red lines signify

enriched localization of Fn1 protein at germ layer borders. Integrin α5β1 is expressed in

all cell types in the pharynx at E8.5 (Chen et al., 2015) and regulates the accrual of

pharyngeal mesoderm from the SHF (green arrows). **A2.** During the 10$^{\text{th}}$ day of mouse

development, integrin a5b1 and Fn1 regulate the remodeling of the plexus endothelium

in the 4$^{\text{th}}$ pharyngeal arch into the PAA. Isl1 lineages are marked in green. NC-derived

cells are in blue. **B.** The expression of integrin a5 in the mesoderm regulates the

differentiation of NC-derived cells into VSMCs. The deletion of integrin α5 in Mesp1

lineage, which includes the SHF, leads to defective NC-to-VSMC differentiation and

results in the regression of the 4$^{\text{th}}$ PAAs leading to IAA-B and RERSA (Liang, et al., *Dev*

Biol 2014). **C.** Fn1 becomes upregulated in NC-derived cells adjacent to the 4th PAA

ECs between E10.5 and E11.5 The expression of integrin α5β1 and Fn1 in the NC-

derived cells is required for NC-to-VSMC differentiation and the stability of the 4$^{\text{th}}$ PAA

(Wang et al, 2016). The deletion of either α5 or Fn1 in the NC (and the surface

ectoderm) leads to IAA-B and RERSA but does not impair PAA formation.

Supplemental Figure 1. Delayed formation of the 4th PAAs in mutants lacking

integrin α5 or Fn1 in the Isl1 lineages. A – B. Quantification of total endothelial cell

numbers in the 4th arches of controls and mutants show similar phenotypes among

integrin α5$^{flox/-}$; Isl1$^{Cre/+}$ and Fn1$^{flox/-}$; Isl1$^{Cre/+}$ embryos. Note the recovery of endothelial

cell numbers at 36 – 40-somite stage. **C.** Combined data comparing endothelial

populations of controls and integrin α5$^{flox/-}$; Isl1$^{Cre/+}$ and Fn1$^{flox/-}$; Isl1$^{Cre/+}$ mutant embryos

at 33 – 34-somite stages. **D.** The proportion of pharyngeal ECs in the plexus is

increased in the mutants relative to controls. **E.** The proportion of endothelial cells in the

PAA is decreased in the mutants relative to controls. Note, 7 of 16 mutants did not have

PAAs (0% endothelial cells in the 4th PAA).

Supplemental Figure 2. The prevalence of cell death, as assayed by the presence

of cleaved caspase 3 or TUNEL signals, was similar in controls and mutants. A, C.

Controls. **B, D.** Mutants. All scale bars are 100 μm.

Supplemental Figure 3. **The differentiation of SHF-derived cells into endothelial**

cells is not affected by the deletion of integrin α5 in the Isl1 lineages. Whole-mount

staining, confocal imaging and 3D reconstruction through the pharyngeal regions of

control (**A, C**) and mutant (**B, D**) embryos. **A – B.** Sagittal optical sections through E9.5

embryos: The majority of VEGFR2^{+} cells express GFP and ERG in the 3rd PAA and in a

more posterior mesenchyme (arrows) in controls and mutants. **C – D.** E10.5 embryos.

3D reconstruction through the pharyngeal region. Open chevrons mark the 4th PAAs.

Note the presence of a very thin PAA in the mutant (**D-D1**). All VERGFR2$^+$ cells are

Pecam1$^+$ in control and in the mutant with defective 4th PAA. Scale bars are 50 μm.

Supplemental Figure 4. Quantification of SHF-derived cells in pharyngeal

mesenchyme and splanchnic mesoderm. E9.5 Isl1$^{Cre/+}$; Rosa$^{nTnG/+}$ embryos were

stained with anti-GFP antibodies, cleared in BABB, and imaged through the entire

pharyngeal region using 25x silicone oil objective N.A. 1.05 and Nikon confocal

microscope. 3D reconstruction and surfacing were done using IMARIS. **A.** Pharyngeal

mesenchyme in the 1st and 2nd pharyngeal arches was surfaced. Dashed line marks the

plane of transverse optical section shown in **A1**. GFP$^+$ cells within the pharyngeal

mesenchyme (yellow) were quantified using the spot function in IMARIS in the entire

volume marked by the yellow surfaces in **A. B –B4.** Splanchnic mesoderm within the

dorsal pericardial wall was surfaced in pink, and pharyngeal mesenchyme was surfaced

in yellow. **B.** Ventral view. **B1.** Right-side view. Dashed line indicates the plane of

section shown in **B3. B2.** A slanted, sagittal/coronal view to visualize both the

splanchnic mesoderm and pharyngeal mesenchyme. **B3**. GFP$^+$ cells in the splanchnic

mesoderm (pink) and in the posterior pharyngeal mesenchyme (yellow) were quantified

using the spot function in IMARIS throughout the entire volume shown in **B**.

Supplemental Figure 5. **Step-wise changes in the configuration of the 4th arch**

endothelium on the 10th day of mouse embryonic development. Control embryos

were stained using antibody to Pecam1. Endothelial cells in the 4th pharyngeal arch

were surface-rendered yellow using IMARIS. First row, 30-somite stage. Endothelium in

the 4th arch is in the form of a plexus of small blood vessels. Second row 33-somite

embryo. A small PAA is seen forming. Red starts mark spaces amidst the

interconnected plexus vessels and the small PAA. Third row, 33-somite stage. A large

PAA is seen with connecting plexus vessels. Spaces (marked by the red stars) are still

seen. Fourth row – 36 – 40 – somite stage. A large PAA is present in the 4th arch by the

evening of the 10th day. DA – dorsal aorta. PAAs are numbers. All scale bars are 50 μm.

Supplemental Figure 6. The expression of integrin $\alpha 5\beta 1$ in the Isl1 lineages

regulates the differentiation of neural crest-derived cells into VSCMs at E11.5

Activation of Notch in the pharyngeal arch mesenchyme is not altered in the mutants.

Coronal section through the pharyngeal regions of Control (**A**) and Mutant (**B**) embryos

were stained to detect green fluorescent protein (GFP, green) marks the Isl1 lineages;

Notch intracellular domain (NICD, orange) is used as the readout of active Notch

signaling; and a smooth muscle actin (αSMA, blue) marks smooth muscle cells. PAAs

are numbered. The magnification is the same in all panels.

Supplemental Figure 7. PAA formation is not affected when integrin α5 is ablated

using Sox17^{2A-iCre} knock-in strain. Whole-mount pictures were taken following India

Ink injections into the hearts of controls and mutants isolated at E10.5. Magnification is

the same in all panels.

References

1.   Stoller JZ and Epstein JA. Cardiac neural crest. *Semin Cell Dev Biol*.
2005;16:704-15.

2.   Schreiber C, Mazzitelli D, Haehnel JC, Lorenz HP and Meisner H. The
interrupted aortic arch: an overview after 20 years of surgical treatment. *Eur J*
Cardiothorac Surg. 1997;12:466-9; discussion 469-70.

3.   Kellenberger CJ. Aortic arch malformations. *Pediatr Radiol*. 2010;40:876-84.

4.   Psillas G, Kekes G, Constantinidis J, Triaridis S and Vital V. Subclavian steal
syndrome: neurotological manifestations. *Acta Otorhinolaryngol Ital*. 2007;27:33-7.

5.   Kirby ML. *Cardiac Development*. New York: Oxford University Press; 2007.

6.   Moon A. Mouse models of congenital cardiovascular disease. *Curr Top Dev Biol*.
2008;84:171-248.

7.   Nagelberg D, Wang J, Su R, Torres-Vazquez J, Targoff KL, Poss KD and Knaut
H. Origin, Specification, and Plasticity of the Great Vessels of the Heart. *Curr Biol*.
2015;25:2099-110.

8.   Paffett-Lugassy N, Singh R, Nevis KR, Guner-Ataman B, O'Loughlin E, Jahangiri
L, Harvey RP, Burns CG and Burns CE. Heart field origin of great vessel precursors
relies on nkx2.5-mediated vasculogenesis. *Nat Cell Biol*. 2013;15:1362-9.

9.   Wang X, Chen D, Chen K, Jubran A, Ramirez A and Astrof S. Endothelium in the
pharyngeal arches 3, 4 and 6 is derived from the second heart field. *Dev Biol*.
2017;421:108-117.

10.   Li P, Pashmforoush M and Sucov HM. Mesodermal retinoic acid signaling
regulates endothelial cell coalescence in caudal pharyngeal arch artery vasculogenesis.
Dev Biol. 2012;361:116-24.

11.   Bremer JL. The development of the aorta and aortic arches in rabbits. *American*
Journal of Anatomy. 1912;13:111-128.

12.   DeRuiter MC, Poelmann RE, Mentink MM, Vaniperen L and Gittenberger-De
Groot AC. Early formation of the vascular system in quail embryos. *Anat Rec*.
1993;235:261-74.

13.   Abrial M, Paffett-Lugassy N, Jeffrey S, Jordan D, O'Loughlin E, Frederick CJ,
3rd, Burns CG and Burns CE. TGF-beta Signaling Is Necessary and Sufficient for
Pharyngeal Arch Artery Angioblast Formation. *Cell Rep*. 2017;20:973-983.

14.   Guner-Ataman B, Paffett-Lugassy N, Adams MS, Nevis KR, Jahangiri L,
Obregon P, Kikuchi K, Poss KD, Burns CE and Burns CG. Zebrafish second heart field
development relies on progenitor specification in anterior lateral plate mesoderm and
nkx2.5 function. *Development*. 2013;140:1353-63.

15.   Guner-Ataman B, Gonzalez-Rosa JM, Shah HN, Butty VL, Jeffrey S, Abrial M,
Boyer LA, Burns CG and Burns CE. Failed Progenitor Specification Underlies the
Cardiopharyngeal Phenotypes in a Zebrafish Model of 22q11.2 Deletion Syndrome. *Cell*
Rep. 2018;24:1342-1354 e5.

16.   Holowiecki A, Linstrum K, Ravisankar P, Chetal K, Salomonis N and Waxman
JS. Pbx4 limits heart size and fosters arch artery formation through partitioning second
heart field progenitors and restricting proliferation. *Development*. 2020.

17.   Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M and Poelmann RE.
Smooth muscle cell origin and its relation to heterogeneity in development and disease.
Arterioscler Thromb Vasc Biol. 1999;19:1589-94.

18.   Bockman DE, Redmond ME, Waldo K, Davis H and Kirby ML. Effect of neural
crest ablation on development of the heart and arch arteries in the chick. *The American*
journal of anatomy. 1987;180:332-41.

19.   Hutson MR and Kirby ML. Model systems for the study of heart development and
disease. Cardiac neural crest and conotruncal malformations. *Semin Cell Dev Biol*.
2007;18:101-10.

20.   Hutson MR, Sackey FN, Lunney K and Kirby ML. Blocking hedgehog signaling
after ablation of the dorsal neural tube allows regeneration of the cardiac neural crest
and rescue of outflow tract septation. *Dev Biol*. 2009;335:367-73.

21.   Rosenquist TH, Kirby ML and van Mierop LH. Solitary aortic arch artery. A result
of surgical ablation of cardiac neural crest and nodose placode in the avian embryo.
Circulation. 1989;80:1469-75.

22.   Keyte A and Hutson MR. The neural crest in cardiac congenital anomalies.
Differentiation; research in biological diversity. 2012;84:25-40.

23.   Coles EG, Gammill LS, Miner JH and Bronner-Fraser M. Abnormalities in neural
crest cell migration in laminin alpha5 mutant mice. *Dev Biol*. 2006;289:218-28.

24.   Cooley MA, Kern CB, Fresco VM, Wessels A, Thompson RP, McQuinn TC, Twal
WO, Mjaatvedt CH, Drake CJ and Argraves WS. Fibulin-1 is required for
morphogenesis of neural crest-derived structures. *Dev Biol*. 2008;319:336-45.

25.   Rydeen AB and Waxman JS. Cyp26 Enzymes Facilitate Second Heart Field
Progenitor Addition and Maintenance of Ventricular Integrity. *PLoS Biol*.
2016;14:e2000504.

26.   Wickstrom SA, Radovanac K and Fassler R. Genetic analyses of integrin
signaling. *Cold Spring Harb Perspect Biol*. 2011;3.

27.   Astrof S. Interactions between neural crest-derived cells and extracellular
microenvironment during cardiovascular development. In: D. W. Desimone and R. P.
Mecham, eds. *Extracellular Matrix in Development* Berlin: Springer Verlag; 2013: 105-
131.

28.   Mittal A, Pulina M, Hou SY and Astrof S. Fibronectin and integrin alpha 5 play
essential roles in the development of the cardiac neural crest. *Mech Dev*. 2010;127:472-
84.

29.   Chen D, Wang X, Liang D, Gordon J, Mittal A, Manley N, Degenhardt K and
Astrof S. Fibronectin signals through integrin alpha5beta1 to regulate cardiovascular
development in a cell type-specific manner. *Dev Biol*. 2015;407:195-210.

30.   Wang X and Astrof S. Isolation of Mouse Cardiac Neural Crest Cells and Their
Differentiation into Smooth Muscle Cells. *Bio Protoc*. 2017;7.

31.   Wang X and Astrof S. Neural crest cell-autonomous roles of fibronectin in
cardiovascular development. *Development*. 2016;143:88-100.

32.   Humphries JD, Byron A and Humphries MJ. Integrin ligands at a glance. *J Cell*
Sci. 2006;119:3901-3.

33.   Hynes RO and Naba A. Overview of the matrisome--an inventory of extracellular
matrix constituents and functions. *Cold Spring Harbor perspectives in biology*.
2012;4:a004903.

34.   Pulina M, Liang D and Astrof S. Shape and position of the node and notochord
along the bilateral plane of symmetry are regulated by cell-extracellular matrix
interactions. *Biology open*. 2014;3:583-90.

35.   George EL, Baldwin HS and Hynes RO. Fibronectins are essential for heart and
blood vessel morphogenesis but are dispensable for initial specification of precursor
cells. *Blood*. 1997;90:3073-81.

36.   George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H and Hynes RO.
Defects in mesoderm, neural tube and vascular development in mouse embryos lacking
fibronectin. *Development*. 1993;119:1079-91.

37.   Georges-Labouesse EN, George EL, Rayburn H and Hynes RO. Mesodermal
development in mouse embryos mutant for fibronectin. *Dev Dyn*. 1996;207:145-56.

38.   Pulina MV, Hou SY, Mittal A, Julich D, Whittaker CA, Holley SA, Hynes RO and
Astrof S. Essential roles of fibronectin in the development of the left-right embryonic
body plan. *Dev Biol*. 2011;354:208-20.

39.   Yang JT, Bader BL, Kreidberg JA, Ullman-Cullere M, Trevithick JE and Hynes
RO. Overlapping and independent functions of fibronectin receptor integrins in early
mesodermal development. *Dev Biol*. 1999;215:264-77.

40.   Yang JT, Rayburn H and Hynes RO. Embryonic mesodermal defects in alpha 5
integrin-deficient mice. *Development*. 1993;119:1093-105.

41.   Mittal A, Pulina M, Hou S and Astrof S. Fibronectin and integrin alpha 5 play
requisite roles in cardiac morphogenesis. *Dev Biol*. 2013;381:73-82.

42.   Sun Y, Liang X, Najafi N, Cass M, Lin L, Cai CL, Chen J and Evans SM. Islet 1 is
expressed in distinct cardiovascular lineages, including pacemaker and coronary
vascular cells. *Dev Biol*. 2007;304:286-96.

43.   Devine WP, Wythe JD, George M, Koshiba-Takeuchi K and Bruneau BG. Early
patterning and specification of cardiac progenitors in gastrulating mesoderm. *eLife*.
2014;3.

44.   Ramirez A and Astrof S. Visualization and Analysis of Pharyngeal Arch Arteries
using Whole-mount Immunohistochemistry and 3D Reconstruction. *J Vis Exp*.
2020;157:e60797.

45.   Fish JE, Cantu Gutierrez M, Dang LT, Khyzha N, Chen Z, Veitch S, Cheng HS,
Khor M, Antounians L, Njock MS, Boudreau E, Herman AM, Rhyner AM, Ruiz OE,
Eisenhoffer GT, Medina-Rivera A, Wilson MD and Wythe JD. Dynamic regulation of
VEGF-inducible genes by an ERK/ERG/p300 transcriptional network. *Development*.
2017;144:2428-2444.

46.   Jia G, Preussner J, Chen X, Guenther S, Yuan X, Yekelchyk M, Kuenne C,
Looso M, Zhou Y, Teichmann S and Braun T. Single cell RNA-seq and ATAC-seq
analysis of cardiac progenitor cell transition states and lineage settlement. *Nat*
Commun. 2018;9:4877.

47.   Verzi MP, McCulley DJ, De Val S, Dodou E and Black BL. The right ventricle,
outflow tract, and ventricular septum comprise a restricted expression domain within the
secondary/anterior heart field. *Dev Biol*. 2005;287:134-45.

48.   Dodou E, Verzi MP, Anderson JP, Xu SM and Black BL. Mef2c is a direct
transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse
embryonic development. *Development*. 2004;131:3931-42.

49.   Papangeli I and Scambler PJ. Tbx1 genetically interacts with the transforming
growth factor-beta/bone morphogenetic protein inhibitor Smad7 during great vessel
remodeling. *Circ Res*. 2013;112:90-102.

50.   Lindsay EA and Baldini A. Recovery from arterial growth delay reduces
penetrance of cardiovascular defects in mice deleted for the DiGeorge syndrome
region. *Human molecular genetics*. 2001;10:997-1002.

51.   Waldo KL, Kumiski D and Kirby ML. Cardiac neural crest is essential for the
persistence rather than the formation of an arch artery. *Dev Dyn*. 1996;205:281-92.

52.   High FA, Zhang M, Proweller A, Tu L, Parmacek MS, Pear WS and Epstein JA.
An essential role for Notch in neural crest during cardiovascular development and
smooth muscle differentiation. *J Clin Invest*. 2007;117:353-63.

53.   High FA, Jain R, Stoller JZ, Antonucci NB, Lu MM, Loomes KM, Kaestner KH,
Pear WS and Epstein JA. Murine Jagged1/Notch signaling in the second heart field
orchestrates Fgf8 expression and tissue-tissue interactions during outflow tract
development. *J Clin Invest*. 2009;119:1986-96.

54.   High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH and Epstein JA.
Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth
muscle development. *Proceedings of the National Academy of Sciences %R*
101073/pnas0709663105. 2008;105:1955-1959.

55.   Manderfield LJ, Aghajanian H, Engleka KA, Lim LY, Lui F, Jain R, Li L, Olson EN
and Epstein JA. Hippo signaling is required for Notch-dependent smooth muscle
differentiation of neural crest. *Development*. 2015.

56.   Manderfield LJ, High FA, Engleka KA, Liu F, Li L, Rentschler S and Epstein JA.
Notch activation of Jagged1 contributes to the assembly of the arterial wall. *Circulation*.
2012;125:314-23.

57.   Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H and Betsholtz C.
Lack of pericytes leads to endothelial hyperplasia and abnormal vascular
morphogenesis. *J Cell Biol*. 2001;153:543-53.

58.   Jiang X, Rowitch DH, Soriano P, McMahon AP and Sucov HM. Fate of the
mammalian cardiac neural crest. *Development*. 2000;127:1607-1616.

59.   Liang D, Wang X, Mittal A, Dhiman S, Hou SY, Degenhardt K and Astrof S.
Mesodermal expression of integrin alpha5beta1 regulates neural crest development and
cardiovascular morphogenesis. *Dev Biol*. 2014;395:232–244.

60.   Engleka KA, Manderfield LJ, Brust RD, Li L, Cohen A, Dymecki SM and Epstein
JA. Islet1 derivatives in the heart are of both neural crest and second heart field origin.
Circ Res. 2012;110:922-6.

61.   van der Flier A, Badu-Nkansah K, Whittaker CA, Crowley D, Bronson RT, Lacy-
Hulbert A and Hynes RO. Endothelial alpha5 and alphav integrins cooperate in
remodeling of the vasculature during development. *Development*. 2010;137:2439-49.

62.   Engert S, Liao WP, Burtscher I and Lickert H. Sox17-2A-iCre: a knock-in mouse
line expressing Cre recombinase in endoderm and vascular endothelial cells. *Genesis*.
2009;47:603-10.

63.   Calmont A, Ivins S, Van Bueren KL, Papangeli I, Kyriakopoulou V, Andrews WD,
Martin JF, Moon AM, Illingworth EA, Basson MA and Scambler PJ. Tbx1 controls
cardiac neural crest cell migration during arch artery development by regulating Gbx2
expression in the pharyngeal ectoderm. *Development*. 2009;136:3173-83.

64.   Gitler AD, Lu MM and Epstein JA. PlexinD1 and semaphorin signaling are
required in endothelial cells for cardiovascular development. *Dev Cell*. 2004;7:107-16.

65.   Merscher S, Funke B, Epstein JA, Heyer J, Puech A, Lu MM, Xavier RJ, Demay
MB, Russell RG, Factor S, Tokooya K, Jore BS, Lopez M, Pandita RK, Lia M, Carrion
D, Xu H, Schorle H, Kobler JB, Scambler P, Wynshaw-Boris A, Skoultchi AI, Morrow BE
and Kucherlapati R. TBX1 is responsible for cardiovascular defects in velo-cardio-
facial/DiGeorge syndrome. *Cell*. 2001;104:619-29.

66.   Phillips HM, Stothard CA, Shaikh Qureshi WM, Kousa AI, Briones-Leon JA,
Khasawneh RR, O'Loughlin C, Sanders R, Mazzotta S, Dodds R, Seidel K, Bates T,

Nakatomi M, Cockell SJ, Schneider JE, Mohun TJ, Maehr R, Kist R, Peters H and Bamforth SD. Pax9 is required for cardiovascular development and interacts with Tbx1 in the pharyngeal endoderm to control 4th pharyngeal arch artery morphogenesis. *Development*. 2019;146.

67.   Macatee TL, Hammond BP, Arenkiel BR, Francis L, Frank DU and Moon AM. Ablation of specific expression domains reveals discrete functions of ectoderm- and endoderm-derived FGF8 during cardiovascular and pharyngeal development. *Development*. 2003;130:6361-74.

68.   Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J and Evans S. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev Cell*. 2003;5:877-89.

69.   Baldini A, Fulcoli FG and Illingworth E. Tbx1: Transcriptional and Developmental Functions. *Current topics in developmental biology*. 2017;122:223-243.

70.   Graham A, Okabe M and Quinlan R. The role of the endoderm in the development and evolution of the pharyngeal arches. *J Anat*. 2005;207:479-87.

71.   Alfano D, Altomonte A, Cortes C, Bilio M, Kelly RG and Baldini A. Tbx1 regulates extracellular matrix-cell interactions in the second heart field. *Human molecular genetics*. 2019;28:2295-2308.

72.   Francou A, Saint-Michel E, Mesbah K and Kelly RG. TBX1 regulates epithelial polarity and dynamic basal filopodia in the second heart field. *Development*. 2014;141:4320-31.

73.   van Bueren KL, Papangeli I, Rochais F, Pearce K, Roberts C, Calmont A, Szumska D, Kelly RG, Bhattacharya S and Scambler PJ. Hes1 expression is reduced in Tbx1 null cells and is required for the development of structures affected in 22q11 deletion syndrome. *Dev Biol*. 2010;340:369-80.

74.   Aghajanian H, Choi C, Ho VC, Gupta M, Singh MK and Epstein JA. Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways. *J Biol Chem*. 2014;289:17971-9.

75.   Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ and Morrisey EE. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J Clin Invest*. 2007;117:1794-804.

76.   Degenhardt K, Singh MK, Aghajanian H, Massera D, Wang Q, Li J, Li L, Choi C, Yzaguirre AD, Francey LJ, Gallant E, Krantz ID, Gruber PJ and Epstein JA. Semaphorin

3d signaling defects are associated with anomalous pulmonary venous connections. *Nat Med*. 2013;19:760-5.

77.   Frank DU, Fotheringham LK, Brewer JA, Muglia LJ, Tristani-Firouzi M, Capecchi MR and Moon AM. An Fgf8 mouse mutant phenocopies human 22q11 deletion syndrome. *Development*. 2002;129:4591-603.

78.   Park EJ, Ogden LA, Talbot A, Evans S, Cai CL, Black BL, Frank DU and Moon AM. Required, tissue-specific roles for Fgf8 in outflow tract formation and remodeling. *Development*. 2006;133:2419-33.

79.   Park EJ, Watanabe Y, Smyth G, Miyagawa-Tomita S, Meyers E, Klingensmith J, Camenisch T, Buckingham M and Moon AM. An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. *Development*. 2008;135:3599-610.

80.   Watanabe Y, Miyagawa-Tomita S, Vincent SD, Kelly RG, Moon AM and Buckingham ME. Role of mesodermal FGF8 and FGF10 overlaps in the development of the arterial pole of the heart and pharyngeal arch arteries. *Circ Res*. 2010;106:495-503.

81.   Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Compernolle V, Dewerchin M, Plaisance S, Vlietinck R, Emanuel B, Gittenberger-de Groot AC, Scambler P, Morrow B, Driscol DA, Moons L, Esguerra CV, Carmeliet G, Behn-Krappa A, Devriendt K, Collen D, Conway SJ and Carmeliet P. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? *Nat Med*. 2003;9:173-82.

82.   Oh J, Richardson JA and Olson EN. Requirement of myocardin-related transcription factor-B for remodeling of branchial arch arteries and smooth muscle differentiation. *Proc Natl Acad Sci U S A*. 2005;102:15122-7.

83.   Hellstrom M, Kalen M, Lindahl P, Abramsson A and Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development*. 1999;126:3047-55.

84.   Scambler PJ. The 22q11 deletion syndromes. *Human molecular genetics*. 2000;9:2421-6.

85.   Momma K. Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome. *Am J Cardiol*. 2010;105:1617-24.

86.   Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, Pramparo T, Jurecic V, Ogunrinu G, Sutherland HF, Scambler PJ, Bradley A and Baldini A. Tbx1

1066 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice.
1067 *Nature*. 2001;410:97-101.

1068 87.   Jerome LA and Papaioannou VE. DiGeorge syndrome phenotype in mice mutant
1069 for the T-box gene, Tbx1. *Nat Genet*. 2001;27:286-91.
1070

FIGURE 1

MEF2C-AHF-DreERT2   Tamoxifen injection at E8.0

VEGFR2 tdTomato   VEGFR2 tdTomato   VEGFR2 ERG

200 µm   100 µm   100 µm

Figure1. Endothelial PAA progenitors are present in the second heart field as early as E7.25. Isl1MerCreMer and MEF2C-AHF-DreERT2 males were mated with the appropriate reporter females (see Methods). E0.5 was considered to be noon on the day of the vaginal plug. Tamoxifen was injected at specified times, embryos were dissected at E10.5, and stained to detect VEGFR2 (blue), ERG (red), or tdTomato (orange). **A.** Sagittal view and 3D reconstruction through the left pharyngeal region. Inset- 3D reconstruction of PAAs. **A1 – A2.** Sagittal optical sections through the embryo shown in **A.** Labeling efficiency was quantified by calculating the ratio of the number of ERG+ tdTomato+ ECs to the total number of ERG+ ECs in PAAs using IMARIS spot function. **B.** Highest labeling of PAA endothelium occurred when tamoxifen was injected at E7.25 in Isl1MerCreMer knockin mice. **B1.** SHF-derived cells continue to be added to the 4th PAA after E9.5. C. Peak labeling of PAA ECs occurred when tamoxifen was injected at E8.0 in MEF2C-AHF-DreERT2 strain. C1. Injection of tamoxifen at E8.5 led to a more efficient labeling of the 4th PAAs than the 3rd and 6th PAAs.

FIGURE 2

Figure 2. Majority of PAA ECs are SHF-derived; there are differences in the contribution of the SHF to the PAA endothelium depending on the strain used. Mef2C-AHF-Cre; ROSG^{mTmG} embryos (35 – 37 somites) were stained with antibodies to VEGFR2 (turquoise) to detect endothelial cells, tdTomato (orange) to detect SHF-derived cells, and DAPI (blue) to stain cell nuclei. **A – A2.** 3D reconstructions of PAAs and their connections with the dorsal aorta (dAo) and the aortic sac (Ao S). **B – B2.** Sagittal optical sections to show the distribution of all SHF-derived cells in the pharyngeal arches. PAAs 3 – 6 are labeled. Magnifications are the same in all panels. All scale bars are 100 μm. **C.** Number of VEGFR2$^+$EGR$^+$ cells in the pharyngeal arches was quantified in 5 E10.5 embryos at 35 – 37 somites using IMARIS. Each dot is one arch. Red line marks the median. Black lines mark the medians. Differences among the three PAA pairs are not significant, p>0.1 by one-way ANOVA with Tukey's correction for multiple testing. **D – E.** The percentage of VEGFR2$^+$EGR$^+$ cells expressing the Cre reporter was determined in each PAA (orange bars). Blue bars are the percent of VEGFR2$^+$EGR$^+$ cells that were not labeled with the Cre reporter. **D.** The use of constitutive Isl1^{Cre} strain resulted in labeling of more than 80% of ECs in the 3rd and 4th PAAs. **E.** The use of Mef2C-AHF-Cre strain resulted in a significantly higher labeling of the 4th PAAs than the 3rd and the 6th. The difference in the labeling efficiency of 6th PAAs between the two strains was not significant, p> 0.2. All statistical analyses were performed using one-way ANOVA with Tukey's correction for multiple testing.

Figure 3. Formation of the 4th PAA is delayed in integrin α5β1[ac]; Isl1[Cre] mutants. α5β1[ac]; Isl1[Cre] control and α5β1[ac]; Isl1[Cre] mutant embryos were dissected at different somite stages at E10.5 and stained to detect Pecam1 PAAs are numbered and somite stages are indicated in the first row. **A, D, G, J.** 3D reconstructions of wholemount Pecam 1 staining (blue) in **B, E, H, K.** PAA endothelium in the 3rd, 4th and 6th arches shown in the row above was surface-rendered white, green and red, respectively. In addition, the plexus endothelium in the 4th arch was surface-rendered in pink. **C, F, I, L.** Left side and ventral view of surface-rendered PAAs and the plexus. Development of the 4th PAAs was specifically affected in the mutants (**E, F**). Magnification is the same in all panels. Scale bar is 100 μm. **M.** Total number of endothelial cells was quantified as described in Methods. Mutants have EC deficiency in the 4th arch at 32 – 33 somites. **N.** The sizes of the 4th arches are comparable between controls and mutants. **O.** EC proliferation in the PAA and plexus of the 4th arches was similar in controls (**C**) and mutants (**M**). In all plots, solid lines mark the median, dashed lines mark the quartiles. Each dot marks one arch. At least 3 mutants and 3 controls were assayed. Statistics were evaluated using 2-tailed, unpaired Student's t test with Welch's correction for unequal standard deviation between samples.

FIGURE 4

Figure 4. The expression of integrin α5 in the Isl1 lineages is required for the accrual of SHF-derived cells to the pharyngeal mesenchyme. Control and mutant embryos carrying the ROSA[mTmG] reporter allele were dissected at E9.5 (18 – 20 somite stage) and stained with DAPI and anti-GFP antibodies. Whole embryos were imaged and the number of GFP+ cells (SHF-derivatives) in the arch mesenchyme, the splanchnic mesoderm, and in the heart was quantified as described in Sup. Fig. 4. **A.** The total number of GFP cells in the mesenchyme of the 1st and 2nd arches was decreased in the mutants. **B.** The total number of GFP+ cells in the pharyngeal mesenchyme corresponding with the future arches 3 – 6 was decreased in the mutants. The number of SHF cells in heart (C) and in the splanchnic mesoderm (D) was not affected. **E.** The proportion of GFP+ cells in the heart relative to GFP+ cells in splanchnic mesoderm was not affected in the mutants. **F.** The proportion of GFP+ cells in the posterior pharyngeal mesenchyme relative to the number of GFP+ cells in splanchnic mesoderm was significantly decreased in the mutants. Each dot marks one embryo, red lines mark medians, dotted lines mark quartiles; p values were determined using unpaired, 2-tailed Student's t tests.

Figure 5. Recovery of EC numbers in integrin α5$^{flox/-}$; Isl1$^{Cre/+}$ mutants. A. Total EC number has recovered in integrin α5$^{flox/-}$; Isl1$^{Cre/+}$ mutants by the 34th somite stage. **B.** Total number of SHF-derived mesodermal cells has recovered in the pharyngeal arches in integrin α5$^{flox/-}$; Isl1$^{Cre/+}$ mutants by the 34th somite stage. **C.** The fraction of SHF-derived ECs in pharyngeal arches is comparable among control and mutant embryos. This fraction was calculated by quantifying the number of GFP$^+$EFG$^+$ cells and dividing by the total number of ERG$^+$ cells in the entire pharyngeal arches (e.g. ECs in PAA and plexus were quantified). Statistical significance was evaluated using one-way ANOVA with Tukey's correction for multiple testing.

FIGURE 6

Figure 6. Integrin α5β1 and Fn1 regulate the remodeling of EC plexus during the remodeling of the 4th pharyngeal arch arteries. A. The proportion of ECs in the 4th PAAs in the mutant is significantly lower than in controls at all stages examined at E10.5. Including the stages when the EC population in the 4th pharyngeal arch has recovered in the mutant; 2-tailed, unpaired Student's t test. **B – C.** Linear regression analyses indicate the absence of linear correlation between the size of the 4th PAA and EC number (**B**) or density (**C**). PAA size is expressed as the percentage of pharyngeal arch endothelial cells in the 4th PAA in control embryos on the y-axis. **D.** Total EC number (x-axis) from mutants with defective (open symbols) or unaffected 4th PAA (closed symbols) were plotted against the size of the 4th PAAs, y- axis. Regression analysis indicated low correlation between these properties. Circles: 32 – 33 somite embryos, boxes: 34 – 35 somite embryos, triangles: 36 – 39 somite embryos. **E.** The rearrangement of the endothelial plexus into the 4th PAAs is evident in mutants relative to controls with the same number of endothelial cells in the 4th arch (red boxes). EC – endothelial cell(s). Controls: α5fl/+; Isl1Cre/+ and Fn1fl/+; Isl1Cre/+ embryos; Mutants: α5fl/-; Isl1Cre/+ and Fn1fl/-; Isl1Cre/+ embryos.

FIGURE 7

Figure 7. The expression of integrin α5β1 in the Isl1 lineages regulates the differentiation of neural crest-derived cells into VSCMs at E11.5 A. PAA perimeter has recovered in size in the mutants by E11.5. **B.** Smooth muscle coverage of the left 4th and left 6th PAA was deficient in the mutants. **C – D.** Despite defective differentiation of NC cells into VSMCs, the activation of Notch in the pharyngeal arch mesenchyme was not altered in the mutants. PAAs are numbered. PAA ECs at E11.5 are derived from the Isl1Cre lineage (green, arrowheads in **C1, C2** and **D1, D2**). **C2 – D2**. VSMC differentiation assayed by the expression of alpha smooth muscle actin (αSMA, blue) is significantly absent around the 4th PAAs in the mutants (compare regions marked by the arrows in **C2** and **D2**). The activation of Notch is assayed by the expression of NICD is not altered in the mutants with defective VSCM differentiation (arrows in **C3,C4** and **D3,D4**). **E.** Fate map using TFAP2αIRESCre shows the location of NC-derived cells in the pharyngeal arches. Note extensive colonization of the mesenchyme between the endodermal pouches (labeled by the TFAP2αIRESCre lineage) by the TFAP2αIRESCre cells are GFP-negative in Isl1Cre strain (arrows in **C1-C2**). **E2**. αSMA+ cells are GFP+ in TFAP2αIRESCre strain. All scale bars are 50 μm. Additional zoom-out views are in Sup. Fig. 6.

FIGURE 8

Figure 8. Cell – ECM interactions play essential roles at multiple stages during the development of the aortic arch and its branches. **A – E.** Depictions of coronal sections through the 4th pharyngeal arch at E10.5. Lineages are marked in green, NC-derived cells are depicted as circles, NC-derived cells next to the PAA endothelium are marked in orange. **A.** The expression of integrin α5β1 and Fn1 in the Isl1 lineages is required for the formation of the 4th PAAs (see **A1** and **A2** in the blue inset) as well as for NC-to-VSMC differentiation. The deletion of integrin α5 or Fn1 in the Isl1 lineages leads to IAA-B and RERSA. **A1 – A2.** Stages during which integrin a5 and Fn1 regulate the 4th PAA formation. **A1.** A schematic of Isl1 lineages (green) in the pharynx at E8.5 – E9.5. Green arrows indicate migration of splanchnic mesoderm cells into the pharyngeal arches. Red lines signify enriched localization of Fn1 protein at germ layer borders. Integrin α5β1 is expressed in all cell types in the pharynx at E8.5 (Chen et al., 2015) and regulates the accrual of pharyngeal mesoderm from the SHF (green arrows). **A2.** During the 10th day of mouse development, integrin α5β1 and Fn1 regulate the remodeling of the plexus endothelium in the 4th pharyngeal arch into the PAA. Isl1 lineages are marked in green. NC-derived cells are in blue. **B.** The expression of integrin α5 in the mesoderm regulates the differentiation of NC-derived cells into VSMCs. The deletion of integrin α5 in Mesp1 lineage, which includes the SHF, leads to defective NC-to-VSMC differentiation and results in the regression of the 4th PAAs leading to IAA-B and RERSA (Liang, et al., *Dev Biol* 2014). **C.** Fn1 becomes upregulated in NC-derived cells adjacent to the 4th PAA ECs between E10.5 and E11.5 The expression of integrin α5β1 and Fn1 in the NC-derived cells is required for NC-to-VSMC differentiation and the stability of the 4th PAA (Wang et al, 2016). The deletion of either integrin α5 or Fn1 in the NC (and the surface ectoderm) leads to IAA-B and RERSA but does not impair PAA formation. **D.** The expression integrin α5 or Fn1 in the SHF is not required for the morphogenesis of the aortic arch and its branches. **E.** The expression of integrin α5 in the endoderm and the pharyngeal endothelia is not required for the development of the aortic arch and its branches.

Supplemental Table 1. Itga5$^{f/f}$ x Itga5$^{+/-}$; Mef2C-AHF-Cre

Genotype	# Observed at Weaning
Itga5$^{f/-}$; Mef2C-AHF-Cre+	14 (22%)
Itga5 $^{f/-}$	12 (19%)
Itga5$^{f/+}$; Mef2C-AHF-Cre+	18 (29%)
Itga5 $^{f/+}$	19 (30%)
Total	63

Supplemental Table 2. Fn1$^{f/f}$ x Fn1$^{+/-}$; Mef2C-AHF-Cre

Genotype	# Observed at Weaning
Fn1$^{f/-}$; Mef2C-AHF-Cre+	23 (31%)
Fn1 $^{f/-}$	15 (20%)
Fn1$^{f/+}$; Mef2C-AHF-Cre+	17 (23%)
Fn1 $^{f/+}$	19 (26%)
Total	74